Company news

Halozyme Therapeutics, Inc. news in 2024

Halozyme Therapeutics, Inc.'s news releases, calls and decks from 2024, newest first.

View company

Halozyme Announces Takeda Received Regulatory Approval for HYQVIA® 10% Subcutaneous Injection Set with ENHANZE® in Japan for Patients with Agammaglobulinemia or Hypogammaglobulinemia

December 29, 2024

Halozyme Announces FDA Approval of Bristol Myers Squibb's Opdivo Qvantig™ with ENHANZE® for Subcutaneous Use in Most Previously Approved Adult Solid Tumor Opdivo® (nivolumab) Indications

December 29, 2024

Halozyme Announces argenx's VYDURA with ENHANZE® was Granted Regulatory Approval in Japan for Chronic Inflammatory Demyelinating Polyneuropathy

December 29, 2024

Halozyme to Present at Upcoming Investor Conferences

November 26, 2024

Halozyme Withdraws Proposal to Acquire Evotec Following Evotec's Unwillingness to Engage in Discussions

November 21, 2024

Halozyme Provides Update on Non-Binding Proposal to Combine with Evotec

November 17, 2024

Halozyme Confirms Proposal to Combine with Evotec for €11.00 Per Share in an All-Cash Transaction

November 13, 2024

Halozyme reports third quarter 2024 financial and operating results

October 30, 2024

Halozyme provides update on licensee co-formulation patent hearing in Europe

October 23, 2024

Halozyme to Report Third Quarter 2024 Financial and Operating Results

October 22, 2024

Halozyme Announces Expansion of Global Collaboration and License Agreement with argenx for ENHANZE®

October 2, 2024

Halozyme Announces FDA Approval of Roche's Subcutaneous OCREVUS ZUNOVO™ with ENHANZE® for People with Relapsing and Primary Progressive Multiple Sclerosis

September 12, 2024

Halozyme Announces FDA Approval of Roche's Tecentriq Hybreza™ With ENHANZE® for Multiple Types of Cancer

September 11, 2024

Halozyme reports second quarter 2024 financial and operating results

August 5, 2024

Halozyme to Report Second Quarter 2024 Financial and Operating Results

July 22, 2024

Halozyme Announces Roche's OCREVUS® SC with ENHANZE® Receives European Commission Approval for Relapsing and Primary Progressive Multiple Sclerosis

June 24, 2024

Halozyme Announces argenx Receives FDA Approval for VYVGART® Hytrulo Co-Formulated with ENHANZE® for Chronic Inflammatory Demyelinating Polyneuropathy

June 20, 2024

Halozyme Raises Full Year 2024 Financial Guidance and Updates 5-Year Financial Outlook

June 5, 2024

Halozyme Announces Issuance of New European Patent for ENHANZE® Drug Delivery Platform

June 4, 2024

Halozyme to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference

June 3, 2024

Halozyme Announces Bristol Myers Squibb Received Updated Action Date from the U.S. Food and Drug Administration for Subcutaneous Nivolumab Co-Formulated with ENHANZE®

May 20, 2024

Halozyme to Participate in Upcoming Investor Conferences

May 7, 2024

Halozyme reports first quarter 2024 financial and operating results

May 6, 2024

Mahesh Krishnan Elected to Halozyme's Board of Directors

April 24, 2024

Halozyme to Report First Quarter 2024 Financial and Operating Results

April 22, 2024

Halozyme reports fourth quarter and full year 2023 financial and operating results

February 19, 2024

Halozyme To Report Fourth Quarter and Full Year 2023 Financial and Operating Results

February 7, 2024

Halozyme Announces Takeda Received European Commission Approval for HYQVIA® Co-formulated with ENHANZE® as Maintenance Therapy for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

January 28, 2024

Halozyme Announces argenx Received Approval in Japan for VYVDURA® (efgartigimod alfa and hyaluronidase-qvfc) Co-Formulated with ENHANZE® for Generalized Myasthenia Gravis

January 17, 2024

Halozyme Announces Takeda Receives FDA Approval for HYQVIA® Co-formulated with ENHANZE® as Maintenance Therapy in Adults with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

January 15, 2024

Halozyme Announces Roche Receives European Commission Approval of Tecentriq® SC with ENHANZE® Representing the EU's First Subcutaneous PD-(L)1 Cancer Immunotherapy for Multiple Cancer Types

January 15, 2024

Halozyme to Host Investor Business Forum and Long-Term Outlook Call

January 11, 2024

Calls in 2024

Decks in 2024